TY - JOUR
T1 - The significance of bone marrow involvement in aggressive lymphomas
T2 - A retrospective comparison of clinical outcomes between peripheral T cell lymphoma and diffuse large B cell lymphoma in China
AU - Yi, Shuhua
AU - An, Gang
AU - Qi, Junyuan
AU - Zou, Dehui
AU - Zhao, Yaozhong
AU - Zhang, Peihong
AU - Chen, Huishu
AU - Wang, Jun
AU - Qiu, Lugui
N1 - Copyright © 2010 S. Karger AG, Basel.
PY - 2010/12
Y1 - 2010/12
N2 - Background: Peripheral T cell lymphomas (PTCL) have been demonstrated to have a poorer prognosis than diffuse large B cell lymphoma (DLBCL) due to a high frequency of bone marrow involvement (BMI). However, the clinical characteristics of PTCL with BMI have not been fully described, and the clinical outcomes of PTCL with BMI and DLBCL with BMI have not been well compared. Methods: The clinical characteristics and survival of 25 nodal PTCL cases with BMI and 42 DLBCL cases with BMI were compared. Results: Most of the PTCL patients with BMI had lymphadenopathy (88%), B symptoms (76%), an elevated LDH level (68%), anemia (64%), splenomegaly (60%), and a poor performance status (52%). Except for the differences of lymphadenopathy and thrombocytopenia between PTCL with BMI and DLBCL with BMI, similarities in gender, age, hepatomegaly, splenomegaly, a bulky mass, B symptoms, elevated LDH, ≥2 extranodal sites, ECOG scores ≥2, anemia, and international prognostic index (IPI) and age-adjusted IPI scores were observed between the 2 groups. The 2 groups also had similar 3-year overall survival (25.8 vs. 30.0%, p = 0.846) and progressive-free survival (21.3 vs. 25.2%, p = 0.815) rates. Conclusions: PTCL with BMI have a similar aggressive course and poor survival compared to DLBCL with BMI. Thus, the immunophenotype of either T or B lineage may not be a crucial prognostic indicator of survival for these 2 aggressive lymphomas. Copyright © 2010 S. Karger AG, Basel.
AB - Background: Peripheral T cell lymphomas (PTCL) have been demonstrated to have a poorer prognosis than diffuse large B cell lymphoma (DLBCL) due to a high frequency of bone marrow involvement (BMI). However, the clinical characteristics of PTCL with BMI have not been fully described, and the clinical outcomes of PTCL with BMI and DLBCL with BMI have not been well compared. Methods: The clinical characteristics and survival of 25 nodal PTCL cases with BMI and 42 DLBCL cases with BMI were compared. Results: Most of the PTCL patients with BMI had lymphadenopathy (88%), B symptoms (76%), an elevated LDH level (68%), anemia (64%), splenomegaly (60%), and a poor performance status (52%). Except for the differences of lymphadenopathy and thrombocytopenia between PTCL with BMI and DLBCL with BMI, similarities in gender, age, hepatomegaly, splenomegaly, a bulky mass, B symptoms, elevated LDH, ≥2 extranodal sites, ECOG scores ≥2, anemia, and international prognostic index (IPI) and age-adjusted IPI scores were observed between the 2 groups. The 2 groups also had similar 3-year overall survival (25.8 vs. 30.0%, p = 0.846) and progressive-free survival (21.3 vs. 25.2%, p = 0.815) rates. Conclusions: PTCL with BMI have a similar aggressive course and poor survival compared to DLBCL with BMI. Thus, the immunophenotype of either T or B lineage may not be a crucial prognostic indicator of survival for these 2 aggressive lymphomas. Copyright © 2010 S. Karger AG, Basel.
KW - Diffuse large B cell lymphoma
KW - Immunophenotype
KW - Peripheral T cell lymphomas
KW - Prognosis
KW - Body Mass Index
KW - Bone Marrow/pathology
KW - Humans
KW - Middle Aged
KW - Lymphoma, T-Cell, Peripheral/blood
KW - Male
KW - Survival Rate
KW - Treatment Outcome
KW - Time Factors
KW - L-Lactate Dehydrogenase/blood
KW - Hemoglobins/metabolism
KW - Female
KW - Aged
KW - Retrospective Studies
KW - Lymphoma, Large B-Cell, Diffuse/blood
UR - http://www.scopus.com/inward/record.url?scp=78449264183&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78449264183&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/c649ff85-32ed-323b-a6cc-f03aafe9aa05/
U2 - 10.1159/000321544
DO - 10.1159/000321544
M3 - Article
C2 - 21099213
SN - 0001-5792
VL - 124
SP - 239
EP - 244
JO - Acta Haematologica
JF - Acta Haematologica
IS - 4
ER -